Showing 11 of 71 recruiting trials for “B-cell chronic lymphocytic leukemia”
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
👨⚕️ Christine E Gruessner, M.D., National Heart, Lung, and Blood Institute (NHLBI)📍 1 site📅 Started Jun 2019View details ↗
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingNCT03501576 ↗
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
RecruitingNCT03342144 ↗
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
RecruitingNCT03375619 ↗
Long-term Follow-up Study of Patients Receiving CAR-T Cells
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RecruitingNCT03197259 ↗
Chronic Lymphocytic Leukemia Registry Study - Multicenter Prospective National Study
A Long-term Extension Study of PCI-32765 (Ibrutinib)
👨⚕️ Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC📍 174 sites📅 Started Sep 2013View details ↗
RecruitingNCT04028531 ↗
Understanding Chronic Lymphocytic Leukemia
← PreviousPage 4 of 4
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →